Share chart Estrella Immunopharma, Inc.
Extended chart
Simple chart
About Estrella Immunopharma, Inc.
Estrella Biopharma, Inc., a preclinical-stage biopharmaceutical company, develops cancer therapeutics. It develops CD19 and CD20-targeted T-cell therapies for the treatment of blood cancers and solid tumors. Estrella Biopharma, Inc. was incorporated in 2022 and is based in Emeryville, California.| IPO date | 2021-09-14 |
|---|---|
| ISIN | US2975841048 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Сайт | https://www.estrellabio.com |
| Цена ао | 0.98 |
| Change price per day: | 0% (0.851) |
|---|---|
| Change price per week: | -4.17% (0.888) |
| Change price per month: | -11.08% (0.957) |
| Change price per 3 month: | -25.98% (1.1497) |
| Change price per half year: | +1.31% (0.84) |
| Change price per year: | -24.02% (1.12) |
| Change price per 3 year: | -91.48% (9.99) |
| Change price per year to date: | -26.64% (1.16) |
|
|
Underestimation
|
Efficiency
|
|||||||||||||||||||||||||||||||||||||
Dividends
|
Debt
|
Growth impulse
|
|||||||||||||||||||||||||||||||||||||
| Institutions | Volume | Share, % |
|---|---|---|
| Owl Creek Asset Management, L.P. | 255000 | 0.72 |
| JANE STREET GROUP, LLC | 20505 | 0.06 |
| Maso Capital Partners Ltd. | 10000 | 0.03 |
| UBS Group AG | 303 | 0 |
| Wells Fargo & Company | 73 | 0 |
| Head | Job title | Payment | Year of birth |
|---|---|---|---|
| Dr. Cheng Liu Ph.D. | CEO, President & Director | N/A | 1967 (58 years) |
| Jiandong Xu | Chief Financial Officer | N/A |
Address: United States, EmeryVille. CA, 5858 Horton Street - open in Google maps, open in Yandex maps
Website: https://www.estrellabio.com
Website: https://www.estrellabio.com
